Cargando…

In silico analysis suggests differential response to bevacizumab and radiation combination therapy in newly diagnosed glioblastoma

Recently, two phase III studies of bevacizumab, an anti-angiogenic, for newly diagnosed glioblastoma (GBM) patients were released. While they were unable to statistically significantly demonstrate that bevacizumab in combination with other therapies increases the overall survival of GBM patients, th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hawkins-Daarud, Andrea, Rockne, Russell, Corwin, David, Anderson, Alexander R. A., Kinahan, Paul, Swanson, Kristin R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Royal Society 2015
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4535409/ https://www.ncbi.nlm.nih.gov/pubmed/26202682 http://dx.doi.org/10.1098/rsif.2015.0388

Ejemplares similares

A patient-specific computational model of hypoxia-modulated radiation resistance in glioblastoma using (18)F-FMISO-PET
por: Rockne, Russell C., et al.
Publicado: (2015)

Modeling Tumor-Associated Edema in Gliomas during Anti-Angiogenic Therapy and Its Impact on Imageable Tumor
por: Hawkins-Daarud, Andrea, et al.
Publicado: (2013)

Patient-Specific Mathematical Neuro-Oncology: Using a Simple Proliferation and Invasion Tumor Model to Inform Clinical Practice
por: Jackson, Pamela R., et al.
Publicado: (2015)

Toward Patient-Specific, Biologically Optimized Radiation Therapy Plans for the Treatment of Glioblastoma
por: Corwin, David, et al.
Publicado: (2013)

Quantifying Uncertainty and Robustness in a Biomathematical Model–Based Patient-Specific Response Metric for Glioblastoma
por: Hawkins-Daarud, Andrea, et al.
Publicado: (2019)

From cells to tissue: How cell scale heterogeneity impacts glioblastoma growth and treatment response
por: Gallaher, Jill A., et al.
Publicado: (2020)

Timing of bevacizumab administration after biopsy for unresectable newly diagnosed glioblastoma
por: Matsuda, Masahide, et al.
Publicado: (2022)

The impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patients
por: Poulsen, Hans Skovgaard, et al.
Publicado: (2014)

Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab
por: Wen, Qiuting, et al.
Publicado: (2014)

The prognosis for patients with newly diagnosed glioblastoma receiving bevacizumab combination therapy: a meta-analysis
por: Liao, Ke-Li, et al.
Publicado: (2018)

Bevacizumab beyond Progression for Newly Diagnosed Glioblastoma (BIOMARK): Phase II Safety, Efficacy and Biomarker Study
por: Nagane, Motoo, et al.
Publicado: (2022)

Advances in the treatment of newly diagnosed glioblastoma
por: Theeler, Brett J., et al.
Publicado: (2015)

A Review of Newly Diagnosed Glioblastoma
por: Oronsky, Bryan, et al.
Publicado: (2021)

The timing of cranial radiation in elderly patients with newly diagnosed glioblastoma multiforme
por: Lai, Rose, et al.
Publicado: (2010)

Avelumab in newly diagnosed glioblastoma
por: Jacques, Francois H, et al.
Publicado: (2021)

The proneural subtype is not associated with survival benefit from bevacizumab in newly diagnosed glioblastoma: a secondary analysis of the GLARIUS trial
por: Weller, Johannes, et al.
Publicado: (2023)

Newly Diagnosed Glioblastoma in Elderly Patients
por: Yuen, Carlen A., et al.
Publicado: (2022)

Risk of Adverse Vascular Events in Newly Diagnosed Glioblastoma Multiforme Patients Treated with Bevacizumab: a Systematic Review and Meta-Analysis
por: Li, Xiaoqing, et al.
Publicado: (2015)

Plasma YKL-40 as a biomarker for bevacizumab efficacy in patients with newly diagnosed glioblastoma in the phase 3 randomized AVAglio trial
por: Boisen, Mogens K., et al.
Publicado: (2017)

Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG)
por: Reyes‐Botero, Germán, et al.
Publicado: (2018)

Improved Outcomes with Intensity Modulated Radiation Therapy Combined with Temozolomide for Newly Diagnosed Glioblastoma Multiforme
por: Aherne, Noel J., et al.
Publicado: (2014)

From Patient-Specific Mathematical Neuro-Oncology to Precision Medicine
por: Baldock, A. L., et al.
Publicado: (2013)

Correction: Newly Diagnosed Glioblastoma in Elderly Patients
por: Yuen, Carlen A., et al.
Publicado: (2022)

Interstitial photodynamic therapy for newly diagnosed glioblastoma
por: Quach, Stefanie, et al.
Publicado: (2023)

Bevacizumab for glioblastoma
por: Narita, Yoshitaka
Publicado: (2015)

Effect of Bevacizumab Plus Temozolomide-Radiotherapy for Newly Diagnosed Glioblastoma with Different MGMT Methylation Status: A Meta-Analysis of Clinical Trials
por: Du, Chigang, et al.
Publicado: (2016)

Impact of Neoadjuvant Bevacizumab on Neuroradiographic Response and Histological Findings Related to Tumor Stemness and the Hypoxic Tumor Microenvironment in Glioblastoma: Paired Comparison Between Newly Diagnosed and Recurrent Glioblastomas
por: Takei, Jun, et al.
Publicado: (2022)

Progression-Free but No Overall Survival Benefit for Adult Patients with Bevacizumab Therapy for the Treatment of Newly Diagnosed Glioblastoma: A Systematic Review and Meta-Analysis
por: Kaka, Nagham, et al.
Publicado: (2019)

Survival with dacarbazine and fotemustine in newly diagnosed glioblastoma multiforme
por: Fazeny-Dörner, B, et al.
Publicado: (2003)

Subclassification of Newly Diagnosed Glioblastomas through an Immunohistochemical Approach
por: Conroy, Siobhan, et al.
Publicado: (2014)

Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome
por: Weller, Michael, et al.
Publicado: (2016)

Radiotherapy for Newly Diagnosed Glioblastoma in the Elderly: What Is the Standard?
por: Wee, Chan Woo
Publicado: (2022)

Definitive vs palliative pelvic radiation for patients with newly diagnosed stage IVB cervical cancer treated with bevacizumab – An exploratory study
por: Wiley, Rachel L., et al.
Publicado: (2022)

Identifying the spatial and temporal dynamics of molecularly-distinct glioblastoma sub-populations
por: Morris, Bethan, et al.
Publicado: (2020)

The prognostic value of nestin expression in newly diagnosed glioblastoma: Report from the Radiation Therapy Oncology Group
por: Chinnaiyan, Prakash, et al.
Publicado: (2008)

Scalp-Sparing Radiation With Concurrent Temozolomide and Tumor Treating Fields (SPARE) for Patients With Newly Diagnosed Glioblastoma
por: Miller, Ryan, et al.
Publicado: (2022)

Days gained response discriminates treatment response in patients with recurrent glioblastoma receiving bevacizumab-based therapies
por: Singleton, Kyle W, et al.
Publicado: (2020)

Bevacizumab for the Treatment of Glioblastoma
por: Gil-Gil, Miguel J., et al.
Publicado: (2013)

Bevacizumab in recurrent glioblastoma
por: Martinez, Nina L., et al.
Publicado: (2019)

Alterations of the tumor microenvironment in glioblastoma following radiation and temozolomide with or without bevacizumab
por: Tamura, Ryota, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_s8gorfubujhi4gmqbst54nsdqn